Format

Send to

Choose Destination
Curr Opin Immunol. 2011 Jun;23(3):407-13. doi: 10.1016/j.coi.2011.04.002. Epub 2011 Apr 21.

Next generation pneumococcal vaccines.

Author information

1
Division of Infectious Diseases, Children's Hospital, Harvard Medical School, Boston, MA, United States.

Abstract

Currently licensed pneumococcal vaccines are based on the generation of antibodies to the pneumococcal polysaccharide, of which there are more than 90 different types. While these vaccines are highly effective against the serotypes included, their high cost and limited serotype coverage limit their usefulness worldwide, particularly in low resource areas. Thus alternative or adjunctive options are being actively pursued. This review will present these various approaches, including variations of the polysaccharide-protein conjugate strategy, protein-based strategies, and whole cell pneumococcal vaccines. The immunological basis for these different approaches is discussed as well.

PMID:
21514128
PMCID:
PMC3109250
DOI:
10.1016/j.coi.2011.04.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center